a16z Podcast | Players and Paths for Healthcare Startups

• The healthcare startup landscape is structured around three primary verticals: tools (enabling drug/therapy/diagnostic development), therapies, and diagnostics, all requiring navigation of complex regulatory, reimbursement, and adoption hurdles.
• The development chronology for human-facing interventions involves four distinct stages: R&D discovery, regulatory approval (proving safety/efficacy to agencies), securing payment models (reimbursement), and educating the healthcare system to drive patient adoption.
• Unlike standard B2B or B2C models, the healthcare sector involves multi-party decision-making and a highly fragmented, non-linear path to market.

Therapeutic Development Paths

• Therapies: Development is a high-barrier, long-duration process requiring proof of concept in cell and animal models, followed by Phase 1, 2, and 3 human clinical trials.
• Diagnostics (LDT Path): Startups can utilize Laboratory-Derived Tests (LDT) within CLIA-certified labs to bypass early FDA review, offering a lower-risk route to initial market entry and faster time-to-revenue.
• Diagnostic (FDA/CLIA Path): Diagnostic devices (e.g., hardware boxes) generally require direct FDA clearance or CLIA certification to ensure reproducible data and robust laboratory processes.

Tool and Platform Go-to-Market Strategies

• Industry Empowerment: Founders can target the US R&D industry directly, which represents a $75 billion annual market, by selling transformative tools that help other players develop better drugs or diagnostics.
• Non-Exclusive Licensing: A viable strategy for broad platforms is selling non-exclusive access to multiple industry players simultaneously, leveraging engineering to avoid locking out competitors while securing volume.
• Case Study: Abc (Atomab): The company successfully built a >$1 billion private valuation by creating a superior monoclonal antibody design tool, monetizing through upfront fees and backend economics tied to successful drug development across partners.
• Case Study: Illumina: Demonstrates how creating a necessary, scalable capability (cheap, reliable genome sequencing) can drive massive research spend and create a near-monopoly position where the platform is essential to the industry.

Strategic Decision Framework for Founders

• Technology-Dependent GTM: The go-to-market strategy must be dictated by the specific nature of the technology; broadly applicable tools favor partnership models, while specific therapeutic platforms may necessitate becoming the drug developer.
• Foundational Requirements: Founders must immediately define three critical variables: the specific evidence needed for proof of concept, the regulatory pathway for approval, and the entity responsible for payment (payer).
• Scope of Expertise: For companies utilizing platforms to elucidate disease biology, partnering is often superior to internal development, as it is impractical to build deep domain expertise across every disease in parallel.